Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | DRD1 | P21728 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28086831 | 0.89 | EGFR (0.80) | EGFRMEN1F2LMNACHRM2 | |
| SCHEMBL28086824 | 0.85 | EGFR (0.73) | EGFRMEN1F2LMNACHRM2 | |
| SCHEMBL28084464 | 0.85 | EGFR (0.73) | EGFRMEN1KMT2ATDO2IMPDH2 | |
| SCHEMBL29504195 | 0.83 | EGFR (1.00) | EGFRMEN1F2LMNACHRM2 | |
| SCHEMBL921632 | 0.83 | EGFR (1.00) | EGFRMEN1F2LMNACHRM2 | |
| SCHEMBL28210778 | 0.81 | EGFR (0.67) | EGFRTDO2IMPDH2MAPTPRKCZ | |
| SCHEMBL8641138 | 0.78 | EGFR (0.64) | EGFRTDO2IMPDH2KDM4E | |
| SCHEMBL24150219 | 0.78 | EGFR (0.63) | EGFRTDO2IMPDH2KDM4EPRKCZ | |
| SCHEMBL24569425 | 0.76 | EGFR (0.59) | EGFRACHEIMPDH2KDM4E | |
| SCHEMBL277540 | 0.75 | EGFR (0.60) | EGFRTDO2IMPDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116770379-A | High corrosion resistant coating, preparation method, electrolyte and application thereof | 聂正圆 | 2023-09-19 | — | — | CN | claimed |
| CN-101402611-A | Compound with anti-leukocythemia liveness and method of preparing the same | UNIV GUANGDONG PHARM (CN) | 2009-04-08 | — | — | CN | claimed |
| WO-2024140595-A1 | TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 珂阑(上海)医药科技有限公司 | 2024-07-04 | — | — | WO | disclosed |
| CN-118255685-A | Tricyclic compound, pharmaceutical composition and application thereof | 珂阑(上海)医药科技有限公司 | 2024-06-28 | — | — | CN | disclosed |
| CN-112538072-B | Aminopyrimidine EGFR inhibitors | 齐鲁制药有限公司 | 2024-02-06 | — | — | CN | disclosed |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2023-10-31 | — | — | US | disclosed |
| CN-111868037-B | Fused cyclic urea derivatives as CRHR2 antagonists | 拉夸里亚创药株式会社 | 2023-10-13 | — | — | CN | disclosed |
| CN-116770379-A | High corrosion resistant coating, preparation method, electrolyte and application thereof | 聂正圆 | 2023-09-19 | — | — | CN | disclosed |
| US-20230165885-A1 | TREATMENT OF EYE DISORDERS WITH URIDINE PHOSPHATE DERIVATIVES | GLIAGUARD, INC. | 2023-06-01 | — | — | US | disclosed |
| CN-115894486-A | Hydrogenated pyridoquinazoline compound, composition and application thereof | 北京赛特明强医药科技有限公司 | 2023-04-04 | — | — | CN | disclosed |
| EP-3774739-B1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC (JP) | 2022-05-11 | — | — | EP | disclosed |
| US-20060116368-A1 | 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | US | disclosed |
| WO-2006058338-A2 | 4 - PIPERIDINECARBOXAMIDE DERIVATIVES AS MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | WO | disclosed |
| CN-1753889-A | Quinazoline compounds | ASTRAZENECA AB (SE) | 2006-03-29 | — | — | CN | disclosed |
| WO-2005090357-A1 | TRICYCLIC BENZOPYRAN COMPOUND AS ANTI-ARRHYTHMIC AGENTS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2005-09-29 | — | — | WO | disclosed |
| EP-1058549-A4 | THROMBIN OR FACTOR Xa INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2003-11-12 | — | — | EP | disclosed |
| US-6602871-B2 | Anticoagulants; compounds of given formula: several types of nitrogen containing heterocycles such as perhydroindolizine, piperazine, pyrimidine | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-08-05 | — | — | US | disclosed |
| US-20020115854-A1 | Thrombin or factor Xa inhibitors | LAM PATRICK Y S (US) | 2002-08-22 | — | — | US | disclosed |
| EP-1058549-A1 | THROMBIN OR FACTOR Xa INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2000-12-13 | — | — | EP | disclosed |
| WO-2000038683-A1 | THROMBIN OR FACTOR Xa INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115854-A1 | Thrombin or factor Xa inhibitors | SERPINC1, TFPI, SPINT2 | EGFR 2920/4885MEN1 1557/4885F2 6/4885 |
| US-20230165885-A1 | TREATMENT OF EYE DISORDERS WITH URIDINE PHOSPHATE DERIVATIVES | P2RY6, P2RY1, P2RY2 | EGFR 3409/4885MEN1 4182/4885F2 4143/4885 |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | CRHR2, CRHR1, CRH | EGFR 4159/4885MEN1 2330/4885F2 3784/4885 |
| US-20060116368-A1 | 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor | VDAC1, TRPV1, HVCN1 | EGFR 2329/4885MEN1 4809/4885F2 4842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.